AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16730318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) intervention
Number of subjects: 32
Study 15643634 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 0
Study 15643634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11330851 — intervention group
Group type: EXPERIMENTAL
Intervention: classroom instruction enhanced by five homework assignments
Number of subjects: 351
Study 8986959 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned developmental instruction strategies
Number of subjects: 0
Study 8280339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 100
Study 8280339 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 100
Study 8280339 — intervention group
Group type: COMPARATOR
Intervention: Control Phase
Number of subjects: 100
Study 3611457 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures of stress
Number of subjects: 0
Study 30185575 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy (ICBT) with therapist support
Number of subjects: 120
Study 30185575 — intervention group
Group type: EXPERIMENTAL
Intervention: Unguided internet-based cognitive behaviour therapy (ICBT)
Number of subjects: 120
Study 30185575 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive behaviour therapy (f2f CBT)
Number of subjects: 120
Study 26961111 — intervention group
Group type: EXPERIMENTAL
Intervention: Total risk management (LDL‐C <80 mg/dL, systolic BP <130 mmHg, and HbA1c <6.5%)
Number of subjects: 73
Study 26961111 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of risk factors achieving target levels
Number of subjects: 73
Study 24976447 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dose of 7.5 mg MTX per week (group 1)
Number of subjects: 100
Study 24976447 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dose of 15 mg MTX per week (group 2)
Number of subjects: 100
Study 21892594 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy (CBT)
Number of subjects: 33
Study 21892594 — intervention group
Group type: COMPARATOR
Intervention: Trauma-focused cognitive therapy (CT)
Number of subjects: 33
Study 21110842 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT)
Number of subjects: 69
Study 21110842 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients carrying at least one val-allele)
Number of subjects: 69
Study 18266402 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily inhaled SFC 50 microg/100 microg
Number of subjects: 0
Study 18266402 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily inhaled FP 100 microg
Number of subjects: 0
Study 18266402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16983913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhiling Capsule (ZC) - whole recipe, administered orally for 2 weeks
Number of subjects: 250
Study 16983913 — intervention group
Group type: EXPERIMENTAL
Intervention: Disassembled recipe 1 (Western medicines) of ZC, administered orally for 2 weeks
Number of subjects: 250
Study 16983913 — intervention group
Group type: EXPERIMENTAL
Intervention: Disassembled recipe 2 (Chinese medicines) of ZC, administered orally for 2 weeks
Number of subjects: 250
Study 16983913 — intervention group
Group type: COMPARATOR
Intervention: Pingxiao Capsule (Control), administered orally for 2 weeks
Number of subjects: 250
Study 14534336 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin (0.3 percent, or 3 mg per milliliter) administered topically, three times daily for 14 days
Number of subjects: 19
Study 14534336 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered topically, three times daily for 14 days
Number of subjects: 19
Study 11264156 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF priming (250 microg/m(2) twice daily for 5 days before treatment)
Number of subjects: 53
Study 11264156 — intervention group
Group type: COMPARATOR
Intervention: Topotecan without GM-CSF priming
Number of subjects: 53
Study 11264156 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF priming
Number of subjects: 53
Study 9247942 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 37
Study 9247942 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mg/kg midazolam
Number of subjects: 37
Study 9247942 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg midazolam
Number of subjects: 37
Study 9247942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 8005970 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid and cyclophosphamide every other month (Gr-I)
Number of subjects: 71
Study 8005970 — intervention group
Group type: COMPARATOR
Intervention: Steroid alone (Gr-II)
Number of subjects: 71
Study 3551327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (preoperative Co‐60 teletherapy + radical surgery)
Number of subjects: 234
Study 3551327 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 234
Study 29093280 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly DPP‐4 inhibitor, trelagliptin
Number of subjects: 49
Study 29093280 — intervention group
Group type: COMPARATOR
Intervention: Daily DPP‐4 inhibitors
Number of subjects: 49
Study 28802598 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.04μg/kg/h)
Number of subjects: 152
Study 28802598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.04μg/kg/h) plus dexmedetomidine (0.06μg/kg/h)
Number of subjects: 152
Study 25573656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-septal RV lead positioning
Number of subjects: 227
Study 25573656 — intervention group
Group type: COMPARATOR
Intervention: Apical RV lead positioning
Number of subjects: 227
Study 23817470 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 g DHA/day from a microalgae source with 2.4 g/day carrier oil for 16 weeks
Number of subjects: 328
Study 23817470 — intervention group
Group type: COMPARATOR
Intervention: 4.0 g/day olive oil for 16 weeks (control)
Number of subjects: 328
Study 20543754 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking cadence of 100 steps per minute
Number of subjects: 75
Study 20543754 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-related variables in walking cadence
Number of subjects: 75
Study 18323500 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC)
Number of subjects: 0
Study 18323500 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin (C+A)
Number of subjects: 0
Study 16581062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclooxygenase‐2 inhibitor parecoxib (n=20)
Number of subjects: 40
Study 16581062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 12974197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks
Number of subjects: 40
Study 12974197 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine 10 mg/day
Number of subjects: 40
Study 12974197 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) 5 mg/kg per day for 8 weeks, then 4 mg/kg per day for 8 weeks (after initial treatment with antihistamines)
Number of subjects: 40
Study 11074106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of violent suicidal behaviour
Number of subjects: 40
Study 11074106 — intervention group
Group type: COMPARATOR
Intervention: Patients without a history of violent suicidal behaviour
Number of subjects: 40
Study 8626361 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 3500
Study 29945673 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 0
Study 29945673 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 0
Study 26827981 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal presurgical orthodontics
Number of subjects: 40
Study 26827981 — intervention group
Group type: COMPARATOR
Intervention: Conventional presurgical orthodontics
Number of subjects: 40
Study 26827981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26275718 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-Centred Counselling (8 weekly sessions lasting up to 1 hour)
Number of subjects: 36
Study 26275718 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Cognitive Behavioural Therapy (up to 8 weeks of self-help resources with guided telephone support lasting 20-30 minutes each)
Number of subjects: 36
Study 24130680 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT+AN (suggestions for analgesia)
Number of subjects: 44
Study 24130680 — intervention group
Group type: COMPARATOR
Intervention: CPT (without suggestions)
Number of subjects: 44
Study 21167166 — intervention group
Group type: EXPERIMENTAL
Intervention: High endogenous testosterone levels
Number of subjects: 154
Study 21167166 — intervention group
Group type: COMPARATOR
Intervention: Low endogenous testosterone levels
Number of subjects: 154
Study 18550339 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 43
Study 18550339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 18550339 — intervention group
Group type: COMPARATOR
Intervention: Galantamine vs Placebo
Number of subjects: 43
Study 15797582 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill cycling at 60 rpm
Number of subjects: 7
Study 15797582 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill cycling at 80 rpm
Number of subjects: 7
Study 15797582 — intervention group
Group type: COMPARATOR
Intervention: Level ground cycling at 80 rpm
Number of subjects: 7
Study 15797582 — intervention group
Group type: COMPARATOR
Intervention: Level ground cycling at 100 rpm
Number of subjects: 7
Study 11944613 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 0
Study 11944613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 0
Study 11944613 — intervention group
Group type: COMPARATOR
Intervention: Molgramostim
Number of subjects: 0
Study 10738357 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 0
Study 10738357 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 8526167 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.14 mg in each nostril twice a day)
Number of subjects: 63
Study 8526167 — intervention group
Group type: COMPARATOR
Intervention: Ebastine tablets (10 mg as a single night dose)
Number of subjects: 63
Study 1780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (one suppository twice a day for 7 days)
Number of subjects: 98
Study 1780092 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (one suppository twice a day for 7 days)
Number of subjects: 98
Study 6801929 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced fluid intake
Number of subjects: 41
Study 6801929 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid deprivation plus DDAVP
Number of subjects: 41
Study 6801929 — intervention group
Group type: COMPARATOR
Intervention: Free fluid intake
Number of subjects: 41
Study 30312118 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month combined aerobic and resistance exercise program
Number of subjects: 206
Study 30312118 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 28736139 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop TDF therapy
Number of subjects: 42
Study 28736139 — intervention group
Group type: COMPARATOR
Intervention: Continue TDF therapy
Number of subjects: 42
Study 26953856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (8-week initial treatment plus a 10-month maintenance phase)
Number of subjects: 42
Study 26953856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction program (10-month maintenance phase)
Number of subjects: 42
Study 24834811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 1066
Study 24834811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1066
Study 21845596 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation haloperidol (0.5‐5 mg daily)
Number of subjects: 44
Study 21845596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21845596 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5‐5 mg daily)
Number of subjects: 44
Study 19492717 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop
Number of subjects: 38
Study 19492717 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond
Number of subjects: 38
Study 19492717 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond
Number of subjects: 38
Study 19492717 — intervention group
Group type: COMPARATOR
Intervention: One-Step Plus
Number of subjects: 38
Study 17872849 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab Group (n = 300): Cervix wiped with a cotton swab before Pap smear
Number of subjects: 616
Study 17872849 — intervention group
Group type: COMPARATOR
Intervention: No Swab Group (n = 316): Cervix not cleaned with a cotton swab before Pap smear
Number of subjects: 616
Study 14965860 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer program for assessing and training motor coordination
Number of subjects: 11
Study 11310459 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine (10 mg/kg)
Number of subjects: 59
Study 11310459 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam (0.7 mg/kg)
Number of subjects: 59
Study 9127921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific low back pain
Number of subjects: 748
Study 9127921 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroups of low back pain
Number of subjects: 748
Study 7885982 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir mesylate (Hoffmann‐La Roche, Nutley, NJ)
Number of subjects: 0
Study 2438876 — intervention group
Group type: EXPERIMENTAL
Intervention: Grenz rays (3 Gy, once a week for 3 weeks)
Number of subjects: 11
Study 2438876 — intervention group
Group type: COMPARATOR
Intervention: Control skin (untreated)
Number of subjects: 11
Study 31919889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 2217
Study 31919889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg
Number of subjects: 2217
Study 31919889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2217
Study 31919889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab (both doses)
Number of subjects: 2217
Study 30942862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise under normobaric hypoxia (fraction of inspired oxygen = 15%)
Number of subjects: 29
Study 30942862 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise under normoxia (fraction of inspired oxygen = 21%)
Number of subjects: 29
Study 30942862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hypoxia and normoxia groups
Number of subjects: 29
Study 28783060 — intervention group
Group type: EXPERIMENTAL
Intervention: Nacadia® therapy garden design
Number of subjects: 0
Study 25998500 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (10 mg daily)
Number of subjects: 53
Study 25998500 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 23003917 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial periodontal treatment (test group, n = 20)
Number of subjects: 40
Study 23003917 — intervention group
Group type: COMPARATOR
Intervention: No periodontal therapy (control group, n = 20)
Number of subjects: 40
Study 20829332 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on mitral regurgitation
Number of subjects: 86
Study 20829332 — intervention group
Group type: COMPARATOR
Intervention: Training on symptomatic aortic stenosis
Number of subjects: 86
Study 20829332 — intervention group
Group type: COMPARATOR
Intervention: Training on scenario with no cardiac murmur
Number of subjects: 86
Study 18716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan monotherapy (VM)
Number of subjects: 140
Study 18716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine monotherapy (AM)
Number of subjects: 140
Study 18716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + ACE inhibitor (VA)
Number of subjects: 140
Study 18716365 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + ACE inhibitor (AA)
Number of subjects: 140
Study 16781297 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 J/cm(2) fluence
Number of subjects: 20
Study 16781297 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 J/cm(2) fluence
Number of subjects: 20
Study 14653370 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (Zovirax) with prednisolone
Number of subjects: 91
Study 14653370 — intervention group
Group type: COMPARATOR
Intervention: Placebo with prednisolone
Number of subjects: 91
Study 10319359 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1000 IU daily)
Number of subjects: 40
Study 10319359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (soya lecithin)
Number of subjects: 40
Study 8726762 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic stent
Number of subjects: 39
Study 8726762 — intervention group
Group type: COMPARATOR
Intervention: Expandable metal stent
Number of subjects: 39
Study 1890479 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 42
Study 1890479 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (IM)
Number of subjects: 42
Study 6191489 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphencyprone
Number of subjects: 27
Study 29460955 — intervention group
Group type: EXPERIMENTAL
Intervention: UFOV assessment at one, two and three months' post-stroke
Number of subjects: 42
Study 29460955 — intervention group
Group type: COMPARATOR
Intervention: UFOV assessment at three months' post-stroke (Control group)
Number of subjects: 42
Study 31058771 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day DHA
Number of subjects: 27
Study 31058771 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day DHA
Number of subjects: 27
Study 31058771 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 27
Study 28259476 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 319
Study 28259476 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line AR-targeted therapy
Number of subjects: 319
Study 28259476 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of somatic deletion in ctDNA
Number of subjects: 319
Study 25538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS) followed by chemotherapy
Number of subjects: 105
Study 25538174 — intervention group
Group type: COMPARATOR
Intervention: Upfront chemotherapy
Number of subjects: 105
Study 25538174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 105
Study 23486643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 64
Study 23486643 — intervention group
Group type: COMPARATOR
Intervention: Other fluoroquinolones
Number of subjects: 64
Study 23486643 — intervention group
Group type: COMPARATOR
Intervention: Nonfluoroquinolones
Number of subjects: 64
Study 22372266 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus FRD EZ appliance
Number of subjects: 24
Study 22372266 — intervention group
Group type: COMPARATOR
Intervention: Activator appliance
Number of subjects: 24
Study 19366755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopic guidance for corticosteroid injections (n=32)
Number of subjects: 65
Study 19366755 — intervention group
Group type: COMPARATOR
Intervention: Blind injections using landmarks (n=33)
Number of subjects: 65
Study 16937961 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-containing supplement (SUPP; n = 17)
Number of subjects: 37
Study 16937961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC; n = 20)
Number of subjects: 37
Study 15252161 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h infusion of 120 g of mixed AAs
Number of subjects: 24
Study 15252161 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h infusion of 50 g of L‐lysine
Number of subjects: 24
Study 15252161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 h infusion of 240 g of mixed AAs
Number of subjects: 24
Study 15252161 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h infusion of 50 g of L‐lysine + L‐arginine (Lys‐Arg)
Number of subjects: 24
Study 15252161 — intervention group
Group type: COMPARATOR
Intervention: No infusion (control)
Number of subjects: 24
Study 11182837 — intervention group
Group type: EXPERIMENTAL
Intervention: BloodLink‐Guideline
Number of subjects: 60
Study 11182837 — intervention group
Group type: COMPARATOR
Intervention: BloodLink‐Restricted
Number of subjects: 60
Study 9036797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 weeks and then once every other week
Number of subjects: 48
Study 9036797 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (no cidofovir until progression documented)
Number of subjects: 48
Study 9036797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir
Number of subjects: 48
Study 9036797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cidofovir with probenecid and saline hydration
Number of subjects: 48
Study 7639363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg intravenously
Number of subjects: 50
Study 7639363 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg orally
Number of subjects: 50
Study 7639363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 3281700 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallamine
Number of subjects: 0
Study 3281700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0
Study 3281700 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium
Number of subjects: 0